Catalyst
Slingshot members are tracking this event:
Results of the MEASURE 1 and MEASURE 2 Phase III studies for Novartis' Cosentyx (secukinumab) in ankylosing spondylitis (AS) were published
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 23, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Measure, Phase Iii, Cosentyx, Secukinumab, Phase 1, Ankylosing Spondylitis
